Syntimmune Closes $50 Million Series B Financing Led by Apple Tree Partners

08:00 EDT 21 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Funds to advance ongoing SYNT001 clinical development, including Phase 1b/2a clinical studies and manufacturing scale-up Syntimmune plans to report SYNT001 clinical data by early 2018 Syntimmune, Inc., a clinical-st...

Other Sources for this Article

Burns McClellan
Justin Jackson, 212-213-0006, ext. 327


More From BioPortfolio on "Syntimmune Closes $50 Million Series B Financing Led by Apple Tree Partners"

Quick Search


Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...